# A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer

> **NCT04094519** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** enzalutamide
- **DRUG:** enzalutamide Placebo
- **DRUG:** digoxin
- **DRUG:** rosuvastatin

## Key facts

- **NCT ID:** NCT04094519
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-27
- **Primary completion:** 2020-12-27
- **Final completion:** 2020-12-27
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04094519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04094519, "A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04094519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*